These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26821205)

  • 41. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
    Gupta G; Giannino V; Rishi N; Glueck R
    Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.
    Lee HJ; Yoon JK; Heo Y; Cho H; Cho Y; Gwon Y; Kim KC; Choi J; Lee JS; Oh YK; Kim YB
    J Microbiol; 2015 Jun; 53(6):415-20. PubMed ID: 26025174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
    Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
    J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
    Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prokaryotic expression of HPV 16 L1 gene and identification of its immune activity].
    Hao DF; Ma ZH; Wang YP; Rexidan ; Zhang FC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):428-31. PubMed ID: 15989783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.
    Lee HJ; Park N; Cho HJ; Yoon JK; Van ND; Oh YK; Kim YB
    Vaccine; 2010 Feb; 28(6):1613-9. PubMed ID: 19961961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
    Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
    Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
    Wang H; Yu JY; Li L
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins.
    Jabbar IA; Fernando GJ; Saunders N; Aldovini A; Young R; Malcolm K; Frazer IH
    Vaccine; 2000 May; 18(22):2444-53. PubMed ID: 10738102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.
    Hancock G; Blight J; Lopez-Camacho C; Kopycinski J; Pocock M; Byrne W; Price MJ; Kemlo P; Evans RI; Bloss A; Saunders K; Kirton R; Andersson M; Hellner K; Reyes-Sandoval A; Dorrell L
    Sci Rep; 2019 Dec; 9(1):18713. PubMed ID: 31822717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES.
    Kim SJ; Lee C; Lee SY; Kim I; Park JS; Sasagawa T; Ko JJ; Park SE; Oh YK
    Gene Ther; 2003 Aug; 10(15):1268-73. PubMed ID: 12858192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.
    Qiu J; Peng S; Ma Y; Yang A; Farmer E; Cheng MA; Roden RBS; Wu TC; Chang YN; Hung CF
    Virology; 2018 Dec; 525():205-215. PubMed ID: 30296681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.
    Zhang T; Xu Y; Qiao L; Wang Y; Wu X; Fan D; Peng Q; Xu X
    Vaccine; 2010 Apr; 28(19):3479-87. PubMed ID: 20211219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.